LP
PTCT icon

LGL Partners’s PTC Therapeutics PTCT Stock Holding History

LGL Partners’s Portfolio PTCT Stock Details PTCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$734K Hold
9,000
– – 0.27% 29
2026
Q1 		$613K Hold
9,000
– – 0.25% 32
2025
Q4 		$684K Sell
9,000
-8,067
-47% -$586K 0.29% 28
2025
Q3 		$1.05M Buy
17,067
+1,067
+7% +$55.6K 0.45% 23
2025
Q2 		$806K Buy
16,000
+4,000
+33% +$190K 0.36% 29
2025
Q1 		$612K Sell
12,000
-16
-0.1% -$798 0.3% 34
2024
Q4 		$542K Buy
12,016
+6
+0% +$257 0.08% 72
2024
Q3 		$446K Buy
12,010
+10
+0.1% +$335 0.06% 75
2024
Q2 		$367K Buy
+12,000
New +$389K 0.05% 79

Other funds holding PTCT

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Toronto Dominion Bank
Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $86.4B AUM 59.51% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $30.6B AUM 61.81% 1-Year Est. Return

LGL Partners's PTCT Position: Q2 2026 in Review

LGL Partners held its PTC Therapeutics (PTCT) position steady in Q2 2026 at 9,000 shares worth $734K. The position accounts for 0.27% of the portfolio, ranked #29.

LGL Partners first reported a position in PTCT in Q2 2024 and has held it in 9 quarters since. The position peaked at $1.05M in Q3 2025. 383 funds tracked by Wall St. Rank hold PTCT as of Q2 2026.

  • LGL Partners held 9,000 shares of PTC Therapeutics worth $734K as of Q2 2026.
  • LGL Partners left its PTC Therapeutics share count unchanged in Q2 2026.
  • PTC Therapeutics made up 0.27% of LGL Partners's portfolio in Q2 2026, its #29 holding.
  • LGL Partners first reported a position in PTC Therapeutics in Q2 2024 and has held it in 9 quarters since.
  • LGL Partners's PTC Therapeutics position peaked at $1.05M in Q3 2025.
  • 383 funds tracked by Wall St. Rank held PTC Therapeutics as of Q2 2026.

Based on LGL Partners's 13F filing for Q2 2026, filed 27 Jul 2026.